Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome in Advanced Solid Tumors
NCT04921878Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2021
- Primary completion
- Apr 2023
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in solid tumor (advanced stage), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose Limit toxicity and Treatment-related adverse events. Started Jul 2021; status: completed.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04921878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04921878.